Clinical Trials Browser

Phase 3 × Urologic Neoplasms × 1 year × Clear all

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT07313891 2026-03-17

BOOST

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07342517 2026-03-17

RESCUE

Phase 3 Withdrawn

Genitourinary

Neoplasms, Urologic Neoplasms

NCT07464145 2026-03-11

RESCUE

Phase 3 Not yet recruiting

393 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

367 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Clinical Trials

EV-309

Savolitinib vs. Sunitinib in MET-driven PRCC.

BOOST

RESCUE

RESCUE

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT